These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 29347858)

  • 1. Where are we with injectables against HIV infection and what are the remaining challenges?
    Hassounah SA; Mesplède T
    Expert Rev Anti Infect Ther; 2018 Feb; 16(2):143-152. PubMed ID: 29347858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Human immunodeficiency virus infection challenges: Current therapeutic limitations and strategies for improved management through long-acting injectable formulation.
    Tanushree ; Sharma A; Monika ; Singh RP; Jhawat V
    Rev Med Virol; 2024 Jul; 34(4):e2563. PubMed ID: 38886179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiretroviral therapy in HIV-infected adolescents: clinical and pharmacologic challenges.
    Dobroszycki J; Lee P; Romo DL; Rosenberg MG; Wiznia A; Abadi J
    Expert Rev Clin Pharmacol; 2017 May; 10(5):509-516. PubMed ID: 28288535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long acting systemic HIV pre-exposure prophylaxis: an examination of the field.
    Lykins WR; Luecke E; Johengen D; van der Straten A; Desai TA
    Drug Deliv Transl Res; 2017 Dec; 7(6):805-816. PubMed ID: 28612340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The promise and pitfalls of long-acting injectable agents for HIV prevention.
    Landovitz RJ; Kofron R; McCauley M
    Curr Opin HIV AIDS; 2016 Jan; 11(1):122-8. PubMed ID: 26633643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Invisible Product: Preferences for Sustained-Release, Long-Acting Pre-exposure Prophylaxis to HIV Among South African Youth.
    Montgomery ET; Atujuna M; Krogstad E; Hartmann M; Ndwayana S; OʼRourke S; Bekker LG; van der Straten A; Minnis AM
    J Acquir Immune Defic Syndr; 2019 Apr; 80(5):542-550. PubMed ID: 30865050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [National consensus document by GESIDA/National Aids Plan on antiretroviral treatment in adults infected by the human immunodeficiency virus (January 2011 update)].
    Panel de expertos de GESIDA y Plan Nacional sobre el Sida
    Enferm Infecc Microbiol Clin; 2011 Mar; 29(3):209.e1-103. PubMed ID: 21388714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of disease, drug and patient adherence on the effectiveness of antiviral therapy in pediatric HIV.
    Piana C; Danhof M; Della Pasqua O
    Expert Opin Drug Metab Toxicol; 2017 May; 13(5):497-511. PubMed ID: 28043170
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment and prevention of HIV infection with long-acting antiretrovirals.
    Benítez-Gutiérrez L; Soriano V; Requena S; Arias A; Barreiro P; de Mendoza C
    Expert Rev Clin Pharmacol; 2018 May; 11(5):507-517. PubMed ID: 29595351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-Acting HIV Drugs for Treatment and Prevention.
    Gulick RM; Flexner C
    Annu Rev Med; 2019 Jan; 70():137-150. PubMed ID: 30355266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engagement in Care, Awareness, and Interest in Long-Acting Injectable Anti-Retroviral Therapy.
    Stout JA; Allamong M; Hung F; Link K; Chan C; Muiruri C; Sauceda J; McKellar MS
    AIDS Behav; 2024 Oct; 28(10):3315-3325. PubMed ID: 38954172
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting approaches for delivery of antiretroviral drugs for prevention and treatment of HIV: a review of recent research.
    Cobb DA; Smith NA; Edagwa BJ; McMillan JM
    Expert Opin Drug Deliv; 2020 Sep; 17(9):1227-1238. PubMed ID: 32552187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-acting injectable for HIV approved for use in the UK.
    Kirby T
    Lancet Infect Dis; 2022 Jan; 22(1):26. PubMed ID: 34953553
    [No Abstract]   [Full Text] [Related]  

  • 15. Long-acting antiviral agents for HIV treatment.
    Margolis DA; Boffito M
    Curr Opin HIV AIDS; 2015 Jul; 10(4):246-52. PubMed ID: 26049949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delivery of long-acting injectable antivirals: best approaches and recent advances.
    Hickey MB; Merisko-Liversidge E; Remenar JF; Namchuk M
    Curr Opin Infect Dis; 2015 Dec; 28(6):603-10. PubMed ID: 26524333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable long-acting human immunodeficiency virus antiretroviral prodrugs with improved pharmacokinetic profiles.
    Krovi SA; Gallovic MD; Keller AM; Bhat M; Tiet P; Chen N; Collier MA; Gurysh EG; Pino EN; Johnson MM; Shamim Hasan Zahid M; Cottrell ML; Pirone JR; Kashuba AD; Kwiek JJ; Bachelder EM; Ainslie KM
    Int J Pharm; 2018 Dec; 552(1-2):371-377. PubMed ID: 30308272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.
    Özdener AE; Park TE; Kalabalik J; Gupta R
    Expert Rev Anti Infect Ther; 2017 May; 15(5):467-481. PubMed ID: 28322067
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current status and prospects of HIV treatment.
    Cihlar T; Fordyce M
    Curr Opin Virol; 2016 Jun; 18():50-6. PubMed ID: 27023283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of Rilpivirine-Resistant HIV-1 in a Seroconverter From the SSAT 040 Trial Who Received the 300-mg Dose of Long-Acting Rilpivirine (TMC278LA).
    Penrose KJ; Parikh UM; Hamanishi KA; Else L; Back D; Boffito M; Jackson A; Mellors JW
    J Infect Dis; 2016 Mar; 213(6):1013-7. PubMed ID: 26563240
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.